Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
2.340
+0.030 (1.30%)
At close: Jul 1, 2025, 4:00 PM
2.350
+0.010 (0.43%)
After-hours: Jul 1, 2025, 7:30 PM EDT
Taysha Gene Therapies Market Cap
Taysha Gene Therapies has a market cap or net worth of $502.31 million as of July 1, 2025. Its market cap has decreased by -31.31% in one year.
Market Cap
502.31M
Enterprise Value
447.34M
1-Year Change
-31.31%
Ranking
Category
Stock Price
$2.34
Market Cap Chart
Since the IPO on September 24, 2020, Taysha Gene Therapies's market cap has decreased from $690.43M to $502.31M, a decrease of -27.25%. That is a compound annual growth rate of -6.45%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 30, 2025 | 495.87M | 39.86% |
| Dec 31, 2024 | 354.55M | 7.14% |
| Dec 29, 2023 | 330.92M | 134.50% |
| Dec 30, 2022 | 141.12M | -68.52% |
| Dec 31, 2021 | 448.22M | -55.28% |
| Dec 31, 2020 | 1.00B | 45.15% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 699.81B |
| Johnson & Johnson | 367.53B |
| AbbVie | 327.88B |
| Novo Nordisk | 307.21B |
| UnitedHealth Group | 283.00B |
| Novartis AG | 236.92B |
| Abbott Laboratories | 236.64B |
| AstraZeneca | 215.00B |